Mr. Henry Dubina reports

TELESCOPE INNOVATIONS REPORTS 60% REVENUE GROWTH IN PRELIMINARY UNAUDITED FISCAL YEAR 2026 RESULTS

Telescope Innovations Corp. had 60-per-cent growth in gross revenue for fiscal 2026, with revenue reaching $9.3-million, compared with $5.8-million in fiscal 2025. The unaudited, preliminary results are for the fiscal year ended Aug. 31, 2026.

Revenue growth was driven by increased activity across the company's three business units, including deliveries of Telescope's SDL platforms, contract research and development services, and sales of its DirectInject-LC technology. The company's SDL platforms continued to gain traction during fiscal 2026, with Telescope expanding its strategic partner network and completing several installations since the beginning of the fiscal year.

"This fiscal year we advanced self-driving laboratories from demonstration to deployment across three continents, and now have SDLs operating with biopharmaceutical partners in North America, Europe and Asia," stated Henry Dubina, chief executive officer. "We are pleased with the strong revenue growth achieved across our business during fiscal 2026. Our results are in line with management's expectations and reflect continued demand for our technologies and services, particularly our self-driving lab platforms, as we expand our customer and strategic partner network. We also continued to invest in infrastructure, commercialization and technology development to support future growth. We invested deliberately to build our team and capacity, and we enter fiscal 2027 with a stronger commercial pipeline and a cost base that no longer carries the significant investor awareness program of the past year, positioning us for a profitable operation going forward."

Preliminary unaudited financial highlights fiscal year ended Aug. 31, 2026 (fiscal 2026)

All figures are in Canadian dollars, are approximate, and are subject to change upon completion of the annual audit and finalization of the fiscal 2026 financial statements.

• Revenue of approximately $9.3-million (fiscal 2025: $5.8-million);
• Operating expenses of approximately $13.9-million (fiscal 2025: $7.3-million), including approximately $2.0-million related to investor awareness and marketing programs that concluded during the fiscal year;
• Net loss of approximately $4.6-million (fiscal 2025: $1.5-million);
• Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) loss of approximately $2.7-million (fiscal 2025: $400,000).

Operational highlights

• Delivered the first SDL in Korea to the Korean Pharmaceutical and Biopharma Manufacturers Association for pharmaceutical research, development and education;
• Installed a second SDL at Pfizer;
• Secured and delivered a third SDL platform deployment, an autonomous crystallization system, with a major global pharmaceutical company for its European operations;
• Completed a private placement for gross proceeds of approximately $6.5-million.

Readers are encouraged to review the company's financial statements and accompanying management discussion and analysis under the company's profile on SEDAR+.

Investor outreach

The company is providing the preliminary results to support its ongoing investor outreach, including participation in investor conferences in Canada and the United States in October, 2026. Details of each event will be announced separately.

About Telescope Innovations Corp.

Telescope Innovations is a leading developer of physical AI systems, including self-driving laboratories, and enabling technologies and services for the global pharmaceutical and high-value chemical industries. The company's self-driving laboratories are autonomous platforms that combine robotics, real-time analytics and artificial intelligence to plan, execute and analyze chemistry experiments with greater speed, consistency and data quality than manual approaches. Telescope also develops and sells enabling technologies, including the DirectInject-LC reaction sampling system, and provides contract process development services. Bio-pharmaceutical, specialty chemical and advanced materials companies use Telescope's products and services to accelerate the development and scale-up of chemical processes, reducing time and cost from laboratory to market.

We seek Safe Harbor.